CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

ProPhase Labs Expects Business Expansion with Key Promotions and Addition to Management Team

ProPhase Labs Expects Business...

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

ProPhase Labs Expects Business Expansion with Key Promotions and Addition to Management Team

ProPhase Labs Expects Business...

Codexis and Merck Renew Supply Agreement for Sitagliptin Enzyme

Life Sciences Review Life Sciences Review | Tuesday, September 21, 2021
Tweet

Codexis and Merck renew supply agreement for the enzyme used in the Sitagliptin manufacturing process.


FREMONT, CA: Codexis, Inc., a leader in enzyme engineering that enables the promise of synthetic biology, has extended its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient (API) in Merck's JANUVIA® and one of the atypical antipsychotic medications.


“Codexis relationship with Merck spans more than a decade, including R&D collaboration, a CodeEvolver® license, and commercial product supply, and we are proud to extend our partnership even further for the supply of this proprietary, high-performance enzyme for the API in JANUVIA®,” says John Nicols, President, and CEO of Codexis. “Our CodeEvolver® enzyme engineering platform enables Codexis and our partners to design unique enzymes with performance improvements that dramatically reduce the cost and improve the efficiency and sustainability of their API manufacturing.”


Codexis and Merck have collaborated on a research and development agreement to develop a novel, proprietary enzyme to act as a biocatalyst in the sitagliptin manufacturing process. The resulting enzyme simplified the manufacturing process and enhanced output while lowering costs and waste. In 2010, the US Environmental Protection Agency (EPA) awarded Codexis and Merck the annual Presidential Green Chemistry Challenge Award for developing this unique biocatalytic technique for sitagliptin production. Codexis and Merck inked a supply deal for the enzyme in 2012 and a multi-year extension in 2015, both of which were set to expire in February 2022. The following extension and amendment cover the licensing and delivery of the proprietary enzyme through December 31, 2026. The extension may be renewed for a further five years if both firms agree.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial
How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/codexis-and-merck-renew-supply-agreement-for-sitagliptin-enzyme-nwid-564.html